Inhibitory effect of endostatin combined with paclitaxel-cisplatin on breast cancer in xenograft-bearing mice

Experimental and Therapeutic Medicine

Volumn 3, Issue 2, 2012, Pages 159-164

  Sun, Jianguo ^a   Deng, Li ^b   Duan, Yuzhong ^a   Chen, Fanglin ^a   Wang, Xinxin ^a   Li, Dezhi ^a   Chen, Zhengtang ^a  

^a THIRD MILITARY MEDICAL UNIVERSITY   (China)

^b Chongqing Maternal and Child Health Care Hospital   (China)

Author keywords

Breast cancer; Chemotherapy; Nude mice; Recombinant human endostatin

Indexed keywords

CISPLATIN; DNA NUCLEOTIDYLEXOTRANSFERASE; PACLITAXEL; RECOMBINANT ENDOSTATIN; VASCULOTROPIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BLOOD VESSEL PARAMETERS; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNOHISTOCHEMISTRY; MALE; MICROVASCULATURE; MICROVESSEL DENSITY; MOUSE; NICK END LABELING; NONHUMAN; SURVIVAL TIME; TUMOR XENOGRAFT;

EID: 84855391831     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2011.384     Document Type: Article

References (20)

1. Folkman J: What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst: 82: 4-6, 1990
2. O'Reilly MS, Boehm T, Shing Y, et al: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88: 277-285, 1997.
3. Kim YM, Hwang S, Pyun BJ, et al: Endostatin blocks VEGF-mediated signalling via direct interaction with KDR/Flk-1. J Biol Chem 277: 27872-27879, 2002.
4. Hanai J, Dhanabal M, Karumanchi SA, et al: Endostatin causes G1 arrest of endothelial cells through inhibition of cyclin D1. J Biol Chem 277: 16464-16469, 2002.
5. MacDonald NJ, Shivers WY, Narum DL, et al: Endostatin binds tropomyosin. A potential modulator of the antitumor activity of endostatin. J Biol Chem 276: 25190-25196, 2001.
6. Balasubramanian SP, Cross SS, Globe J, et al: Endostatin gene variation and protein levels in breast cancer susceptibility and severity. BMC Cancer 7: 107-114, 2007.
7. Wang JW, Sun Y, Liu YY, et al: Results of randomized, multicenter, double-blind phase III trial of rh-endostatin (YH-16) in treatment of advanced non-small cell lung cancer patients. Zhongguo Fei Ai Za Zhi 8: 283-290, 2005.
8. Yang L, Wang JW, Sun Y, et al: Randomized phase II trial on escalated doses of Rh-endostatin (YH-16) for advanced non-small cell lung cancer. Zhonghua Zhong Liu Za Zhi 28: 138-141, 2006.
9. Teh SH, Hill AD, Lee AW, et al: Raised plasma endostatin levels correlate inversely with breast cancer angiogenesis. J Surg Res 116: 165-171, 2004.
10. Zhao J, Yan F, Ju H, et al: Correlation between serum vascular endothelial growth factor and endostatin levels in patients with breast cancer. Cancer Lett 204: 87-95, 2004.
11. Liby K, Neltner B, Mohamet L, et al: Endostatin expression by MDA-MB-435 breast cancer cells effectively inhibits tumor growth. Cancer Biol Ther 2: 48-52, 2003.
12. Chen QR, Kumar D, Stass SA, et al: Liposomes complexed to plasmids encoding angiostatin and endostatin inhibit breast cancer in nude mice. Cancer Res 59: 3308-3312, 1999.
13. Sun JG, Wang Y, Chen ZT, et al: Detection of lymphangiogenesis in non-small cell lung cancer and its prognostic value. J Exp Clin Cancer Res 28: 21-27, 2009.
14. Uzzan B, Nicolas P, Cucherat M, et al: Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res 64: 2941-2955, 2004.
15. Byrnes K, White S, Chu Q, et al: High eIF4E, VEGF and microvessel density in stage I to III breast cancer. Ann Surg 243: 684-690, 2006.
16. Bachelot T, Ratel D, Menetrier-Caux C, et al: Autoantibodies to endostatin in patients with breast cancer: correlation to endostatin levels and clinical outcome. Br J Cancer 94: 1066-1070, 2006.
17. Jia LJ, Xu HM, Ma DY, et al: Enhanced therapeutic effect by combination of tumor-targeting Salmonella and endostatin in murine melanoma model. Cancer Biol Ther 4: 840-845, 2005.
18. Luo X, Slater JM and Gridley DS: Enhancement of radiation effects by pXLG-mEndo in a lung carcinoma model. Int J Radiat Oncol Biol Phys 63: 553-564, 2005.
19. Schmidt M, Schler G, Gruensfelder P, et al: Differential gene expression in a paclitaxel-resistant clone of a head and neck cancer cell line. Eur Arch Otorhinolaryngol 263: 127-134, 2006.
20. Zhao GZ, Qi XD and Chang ZK: Inhibitory effect of recombinant human endostatin combined with rAd/p53 on graft model of human breast cancer in nude mice. Chin J Cancer Res 17: 843-846, 2007.